Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 6Phase 3 3Phase 4 2Phase 2/3 2Phase 1/2 2Phase NA 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3

Conditions

Myelodysplastic Syndromes 87Leukemia, Myelogenous, Chronic, BCR-ABL Positive 71Leukemia, Myeloid, Acute 66Leukemia 64Myeloproliferative Disorders 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Primary Myelofibrosis 39Leukemia, Myeloid, Chronic-Phase 39Leukemia, Myelomonocytic, Chronic 38Polycythemia Vera 32Lymphoma, Non-Hodgkin 29Lymphoma 29Multiple Myeloma 28Leukemia, Lymphocytic, Chronic, B-Cell 28Hodgkin Disease 27Lymphoma, Large B-Cell, Diffuse 26Lymphoma, Mantle-Cell 25Burkitt Lymphoma 25Leukemia, Myeloid, Accelerated Phase 24Lymphoma, Large-Cell, Immunoblastic 23Lymphoma, Follicular 23Lymphoma, B-Cell, Marginal Zone 23Blast Crisis 23Thrombocythemia, Essential 20Lymphoma, T-Cell, Cutaneous 19Leukemia, Hairy Cell 18Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 17Anemia, Refractory, with Excess of Blasts 17Neoplasms, Plasma Cell 16Myelodysplastic-Myeloproliferative Diseases 16

Interventions

masitinib 2Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Mastocytosis, Systemic × Myeloid × Clear all
NCT03401060 2026-03-31

DenosuMast

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed
24 enrolled
Myeloid

Osteoporosis, Mastocytosis, Systemic

NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

AB Science

Phase 3 Unknown
140 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT00814073 2019-12-03

AB06006

AB Science

Phase 3 Completed
135 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡